Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review

Detalhes bibliográficos
Autor(a) principal: Chaves, Ana Thereza
Data de Publicação: 2022
Outros Autores: Oliveira, Ana Laura Grossi de, Guimarães, Nathalia Sernizon, Magalhães, Isabela Cristina, Menezes, Cristiane Alves da Silva, Rocha, Manoel Otávio da Costa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista do Instituto de Medicina Tropical de São Paulo
Texto Completo: https://www.revistas.usp.br/rimtsp/article/view/199565
Resumo: Chronic Chagas Cardiomyopathy (CCC) is the most prevalent type of myocarditis and the main clinical form of the Chagas disease, which has peculiarities such as focal inflammation, structural derangement, hypertrophy, dilation, and intense reparative fibrosis. Many cellular compounds contribute to CCC development. Galectin-3 is a partaker in inflammation and contributes to myocardial fibrosis formation. Some studies showed the connection between Galectin-3 and fibrosis in Chagas disease but are still inconclusive on the guidance for the early implementation of pharmacological therapy. This systematic review evaluated Galectin-3 as a biomarker for fibrosis intensity in CCC. Two independent reviewers have searched five databases (PubMed, EMBASE, Cochrane Library, Scopus, and Lilacs), using the following search terms: galectin-3, biomarkers, fibrosis, Chagas cardiomyopathy, and Chagas disease. Overall, seven studies met the inclusion criteria and made up this review. There were four trials conducted through animal model experiments and three trials with humans. Experimental data in mice indicate an association between Galectin-3 expression and fibrosis in CCC (75% of studies). Data from human studies showed no direct connection between myocardial fibrosis and Galectin-3 expression (80% of studies). Thus, human findings do not provide significant evidence indicating that Galectin-3 is related to fibrosis formation in Chagas disease. Based on the analyzed studies, it is suggested that Galectin-3 might not be a good fibrosis marker in CCC.
id IMT-1_59dca7ba98fb5e2d63caeba71c7a0b85
oai_identifier_str oai:revistas.usp.br:article/199565
network_acronym_str IMT-1
network_name_str Revista do Instituto de Medicina Tropical de São Paulo
repository_id_str
spelling Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic reviewGalectin-3Chronic Chagas CardiomyopathyFibrosisChronic Chagas Cardiomyopathy (CCC) is the most prevalent type of myocarditis and the main clinical form of the Chagas disease, which has peculiarities such as focal inflammation, structural derangement, hypertrophy, dilation, and intense reparative fibrosis. Many cellular compounds contribute to CCC development. Galectin-3 is a partaker in inflammation and contributes to myocardial fibrosis formation. Some studies showed the connection between Galectin-3 and fibrosis in Chagas disease but are still inconclusive on the guidance for the early implementation of pharmacological therapy. This systematic review evaluated Galectin-3 as a biomarker for fibrosis intensity in CCC. Two independent reviewers have searched five databases (PubMed, EMBASE, Cochrane Library, Scopus, and Lilacs), using the following search terms: galectin-3, biomarkers, fibrosis, Chagas cardiomyopathy, and Chagas disease. Overall, seven studies met the inclusion criteria and made up this review. There were four trials conducted through animal model experiments and three trials with humans. Experimental data in mice indicate an association between Galectin-3 expression and fibrosis in CCC (75% of studies). Data from human studies showed no direct connection between myocardial fibrosis and Galectin-3 expression (80% of studies). Thus, human findings do not provide significant evidence indicating that Galectin-3 is related to fibrosis formation in Chagas disease. Based on the analyzed studies, it is suggested that Galectin-3 might not be a good fibrosis marker in CCC.Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo2022-06-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/rimtsp/article/view/19956510.1590/S1678-9946202264045 Revista do Instituto de Medicina Tropical de São Paulo; Vol. 64 (2022); e45Revista do Instituto de Medicina Tropical de São Paulo; Vol. 64 (2022); e45Revista do Instituto de Medicina Tropical de São Paulo; v. 64 (2022); e451678-99460036-4665reponame:Revista do Instituto de Medicina Tropical de São Pauloinstname:Instituto de Medicina Tropical (IMT)instacron:IMTenghttps://www.revistas.usp.br/rimtsp/article/view/199565/183587Copyright (c) 2022 Ana Thereza Chaves, Ana Laura Grossi de Oliveira, Nathalia Sernizon Guimarães, Isabela Cristina Magalhães, Cristiane Alves da Silva Menezes, Manoel Otávio da Costa Rochahttps://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessChaves, Ana Thereza Oliveira, Ana Laura Grossi de Guimarães, Nathalia SernizonMagalhães, Isabela Cristina Menezes, Cristiane Alves da Silva Rocha, Manoel Otávio da Costa 2022-10-10T13:01:46Zoai:revistas.usp.br:article/199565Revistahttp://www.revistas.usp.br/rimtsp/indexPUBhttps://www.revistas.usp.br/rimtsp/oai||revimtsp@usp.br1678-99460036-4665opendoar:2022-12-13T16:53:33.834933Revista do Instituto de Medicina Tropical de São Paulo - Instituto de Medicina Tropical (IMT)true
dc.title.none.fl_str_mv Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review
title Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review
spellingShingle Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review
Chaves, Ana Thereza
Galectin-3
Chronic Chagas Cardiomyopathy
Fibrosis
title_short Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review
title_full Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review
title_fullStr Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review
title_full_unstemmed Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review
title_sort Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review
author Chaves, Ana Thereza
author_facet Chaves, Ana Thereza
Oliveira, Ana Laura Grossi de
Guimarães, Nathalia Sernizon
Magalhães, Isabela Cristina
Menezes, Cristiane Alves da Silva
Rocha, Manoel Otávio da Costa
author_role author
author2 Oliveira, Ana Laura Grossi de
Guimarães, Nathalia Sernizon
Magalhães, Isabela Cristina
Menezes, Cristiane Alves da Silva
Rocha, Manoel Otávio da Costa
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Chaves, Ana Thereza
Oliveira, Ana Laura Grossi de
Guimarães, Nathalia Sernizon
Magalhães, Isabela Cristina
Menezes, Cristiane Alves da Silva
Rocha, Manoel Otávio da Costa
dc.subject.por.fl_str_mv Galectin-3
Chronic Chagas Cardiomyopathy
Fibrosis
topic Galectin-3
Chronic Chagas Cardiomyopathy
Fibrosis
description Chronic Chagas Cardiomyopathy (CCC) is the most prevalent type of myocarditis and the main clinical form of the Chagas disease, which has peculiarities such as focal inflammation, structural derangement, hypertrophy, dilation, and intense reparative fibrosis. Many cellular compounds contribute to CCC development. Galectin-3 is a partaker in inflammation and contributes to myocardial fibrosis formation. Some studies showed the connection between Galectin-3 and fibrosis in Chagas disease but are still inconclusive on the guidance for the early implementation of pharmacological therapy. This systematic review evaluated Galectin-3 as a biomarker for fibrosis intensity in CCC. Two independent reviewers have searched five databases (PubMed, EMBASE, Cochrane Library, Scopus, and Lilacs), using the following search terms: galectin-3, biomarkers, fibrosis, Chagas cardiomyopathy, and Chagas disease. Overall, seven studies met the inclusion criteria and made up this review. There were four trials conducted through animal model experiments and three trials with humans. Experimental data in mice indicate an association between Galectin-3 expression and fibrosis in CCC (75% of studies). Data from human studies showed no direct connection between myocardial fibrosis and Galectin-3 expression (80% of studies). Thus, human findings do not provide significant evidence indicating that Galectin-3 is related to fibrosis formation in Chagas disease. Based on the analyzed studies, it is suggested that Galectin-3 might not be a good fibrosis marker in CCC.
publishDate 2022
dc.date.none.fl_str_mv 2022-06-29
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/rimtsp/article/view/199565
10.1590/S1678-9946202264045
url https://www.revistas.usp.br/rimtsp/article/view/199565
identifier_str_mv 10.1590/S1678-9946202264045
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/rimtsp/article/view/199565/183587
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by-nc/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo
publisher.none.fl_str_mv Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo
dc.source.none.fl_str_mv Revista do Instituto de Medicina Tropical de São Paulo; Vol. 64 (2022); e45
Revista do Instituto de Medicina Tropical de São Paulo; Vol. 64 (2022); e45
Revista do Instituto de Medicina Tropical de São Paulo; v. 64 (2022); e45
1678-9946
0036-4665
reponame:Revista do Instituto de Medicina Tropical de São Paulo
instname:Instituto de Medicina Tropical (IMT)
instacron:IMT
instname_str Instituto de Medicina Tropical (IMT)
instacron_str IMT
institution IMT
reponame_str Revista do Instituto de Medicina Tropical de São Paulo
collection Revista do Instituto de Medicina Tropical de São Paulo
repository.name.fl_str_mv Revista do Instituto de Medicina Tropical de São Paulo - Instituto de Medicina Tropical (IMT)
repository.mail.fl_str_mv ||revimtsp@usp.br
_version_ 1798951656476377088